Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

KOAN CORDIALS ARE NOW AVAILABLE FOR DELIVERY THROUGHOUT CALIFORNIA

Resonate Blends, Inc

Koan, a Resonate Blends brand, is leading a new area of plant-based wellness with the direct-to-consumer launch of the world’s first cannabis cordials - non-alcoholic, single-dose, plant-derived liquids designed to help mindful consumers to find inspiration, restore balance, and improve the quality of their lives. By combining the wisdom of traditional, holistic wellness practices with cutting-edge science and technology, Koan has developed a brand-new way to harness the wide-ranging benefits of cannabis, utilizing various ratios of THC and CBD, along with botanical terpenes, adaptogens, and other plant extracts to deliver precise and consistent life-enhancing experiences. The six cordials - Calm, Balance, Play, Create, Delight, and Wonder – have the fast on-set of a tincture, the long duration of an edible, and the ease and social benefits of a beverage all in one single-dose bottle. Calm, for example, has a large concentration of CBD with low levels of THC ensuring a profoundly calming experience without getting you high. The low level of THC amplifies the benefits of natural plant extracts including Linalool—known to help treat anxiety, depression, and insomnia—Beta-Caryophyllene, an anti-inflammatory, and Limonene—a naturally-derived anti-depressive—to help ease stress and return to a comfortable and functional mind/body state. On the other extreme is Koan's Wonder formulation carefully crafted to support consumers in every way when their goal is to ponder the infinite. Wonder has higher levels of THC with low levels to CBD designed to help refine the powerful experience. Koan's other blends of Cordials enhance creativity, bring a feeling of enchantment, or unleash a feeling of energy, joy, and more. The full range of products is designed to help those using cannabis in an intentional way to find what they are looking for with precision, consistency, and refinement. “At Koan we’re mastering the art of experience. It’s more than science, it’s our passion - refining, amplifying, and calibrating cannabis so you can always find what you are looking for. We are deeply enmeshed in the science, we have two patents pending supporting our formulations, processes, and bioavailability to ensure that consumers get exactly what they expect, every time, from our products,” said Geoff Selzer, CEO and Founder. “We are delighted to partner with Grassdoor for our direct to home delivery ensuring that all of our customers can get our products whenever they choose in the most convenient, safe, discrete, and reliable fashion possible.” Koan is committed to demystifying cannabis and harnessing its impactful ingredients to create products that support intentional and mindful use as a core part of daily wellness—physical, spiritual, and most importantly, emotional. Through precision crafting, Koan invites a general sense of well-being, lean-in awareness and presence rather than the “check-out high” normally associated with most cannabis-based products. The single-dose cordials are artfully designed to be both portable and discrete, with fast-acting ingredients that allow a quick onset for a long-lasting experience of up to four hours. The delightful citrus and botanical notes of the cordials can be enjoyed directly out of the bottle or poured into any beverage or one of Koan’s signature cannabis cocktail recipes. Koan Cordials are now available for purchase directly at https://koan.life. Koan provides the option to order individual cordial three packs, or in themed bundles such as the Serenity Bundle, Engage Bundle, or the Experience Bundle. Koan has proudly partnered with Grassdoor, the premier direct-to-consumer e-commerce solution for cannabis brands in California, to allow consumers to shop Koan’s portfolio of Cordials with same-day delivery across Southern California (including Los Angeles and San Diego) and Northern California (including San Francisco, San Jose, and Oakland). Grassdoor is one of the largest end-to-end delivery solutions in cannabis, providing same-day delivery to 75% of the population of California. ABOUT RESONATE BLENDS, INC. Resonate Blends, Inc. (OTCQB:KOAN) develops Koan Cordials, meticulously formulated blends of THC, CBD, Terpenes, and Botanicals that provide a refined cannabis experience. Unlike strain-based or full-spectrum products, Koan Cordials are scientifically crafted to highlight specific cannabis characteristics, with predictable experiences and intensity allowing people to tap into specific feelings in a new, better way. ABOUT GRASSDOOR Grassdoor is the premier delivery marketplace and direct-to-consumer ecommerce platform in cannabis, providing customers same-day delivery of top brands in 45 minutes or less throughout California, including Los Angeles, Orange County, San Diego, Ventura, San Francisco, San Jose, Oakland, and more. In addition to being the fastest licensed delivery service in the state, Grassdoor aims to be the safest, friendliest, and most reliable cannabis delivery solution worldwide. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of forward-looking statements include, among others, statements we make regarding guidance relating to net income; anticipated customer onboardings; and expected operating results, such as revenue growth and earnings. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set out in the Company's SEC filings. These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements. Contact Details BPCM Katie Bell +1 323-655-5541 koancordials@bpcm.com Company Website https://www.resonateblends.com

October 13, 2021 08:03 AM Pacific Daylight Time

Holland & Barrett backs Floe Oral Care to tackle gum disease via salivary biomarkers

Floe Oral Care

Floe Oral Care, the oral healthcare business dedicated to improving oral and systemic health by means of a direct-to-consumer subscription, has secured £350k from a group of high profile investors including Holland & Barrett, Lord Mervyn Davies, Tim Farazmand, Professor John Deanfield CBE, Sir Nigel Rudd, and Julio Bruno. Existing shareholders Stephen Welton, Dr. Jose Navarro, and Charles Southey are also following on. Founded by Anglo-Spanish duo Will Welton and Javier Navarro, Floe is an online subscription service on a mission to address the UK’s ‘dental care timebomb’ by building a preventative routine for consumers and providing vital insights into undetected gum disease. Will Welton, Co-founder at Floe Oral Care said: “If your mouth is the gateway to your body, then protecting it requires not only using the right products but also visibility of what condition your gums are in. The impact of gum disease is significant, and the prevalence of periodontitis has barely changed over the last 20 years. Our mission is to build a service that both tracks and improves oral and systemic health. We want to encourage a pro-active relationship with dental care by capturing and contextualising oral health data, and are thrilled to be bringing on board a fantastic group of investors from business and healthcare as well as an excellent and highly relevant corporate partner. This is a great platform for the next stage of our development” Periodontitis is now the sixth most prevalent disease in the world, and according to research led by The Economist Intelligence Unit (IEU), costs the UK £6.4bn a year in treatment. Nearly half the adults in the UK have some form of periodontal disease, which has increasingly been shown to raise the risk of serious health conditions including cardiovascular disease and diabetes. Its awareness has remained low however amongst the general public and other health professionals - it’s often referred to as a silent killer - with the study showing that three out of four adults with periodontitis do not know they have the condition at all. Tamara Rajah MBE, Chief Business & Science Officer, Holland and Barrett: “H&B are committed to making health and wellness a way of life for everyone, and to supporting early-stage innovation in wellness as part of our strategy. Recognising that effective oral health management can disproportionately impact an individual’s overall health and wellness, coupled with our interest about the potential of diagnostics, makes Floe very exciting for us. We look forward to working with Will, Javier and the team at Floe to optimise the way we manage our oral health and improve lives.” Floe is building a data driven approach, designed to cast light on untreated periodontitis and put the right measures in place to improve it. The service will track gum health via proprietary at home saliva testing whilst delivering essential products to support your oral health. Floe launched their core dental kit in August 2020, delivering their own unique toothpaste formulations (Dusk and Dawn), an ultra-soft toothbrush, and charcoal dental floss, delivered every three months to improve preventative habits in a more sustainable way. The products are all built with the environment in mind, including a free-returns service collecting used products for specialist recycling when subscribers' new boxes arrive. Julio Bruno, CEO of Time Out Group plc, will be joining the board as a Non-Executive Director whilst Stephen Welton, founder and Executive Chairman of BGF, the UK’s largest growth capital investor, will remain as the Chairman. Professor John Deanfield CBE joins Floe as Chief Medical Officer, to put together a world leading Advisory Board to inform the strategy of the saliva testing and future healthcare products. Professor Deanfield is one of the leading cardiologists in the UK and has published several papers on the linkage between oral and systemic health. Professor John Deanfield CBE commented: “We now understand the big impact oral health can have on important diseases in the rest of the body. This underpins a new opportunity to benefit from a change in approach to oral health – I am excited to be joining Floe to help address this.” About Floe Oral Care Floe Oral Care is a subscription service providing core dental products/ services on a quarterly basis with a closed loop recycling process to ensure that plastic doesn’t end up in the ocean. It was co-founded by William Welton and Javier Navarro to deliver technology enabled dental healthcare solutions whilst protecting the planet’s environment. Javier comes from a family of dentists and spent the first part of his career in banking. Will’s background is in consumer goods with commercial roles within the drinks industry and e-commerce. For careers please get in touch via CV and covering letter to hello@getfloe.com. About Holland & Barrett Holland & Barrett is the UK’s leading wellness retailer* and one of the largest in Europe. We make health and wellness and way of life for everyone, with a leading range of own brand, innovative vitamins, supplements, specialist food, sports nutrition and ethical beauty brands. Established in 1870, Holland & Barrett has been trusted for wellness for over 150 years and is owned by the Letter One Retail Group (L1 Retail). Holland & Barrett has a retail presence of more than 1000 stores across 16 countries worldwide, including over 800 in the UK and Ireland**, as well as a rapidly expanding e-commerce business. Holland & Barrett’s colleagues are “qualified to advise” with in depth training in nutrition and supplements to give accessible personalised advice to customers on their individual needs. *Kantar Brand Tracking – health and wellness retailers March 2021 ** up to 30 September 2020. Contact Details Floe Oral Care Bilal Mahmood +44 7714 007257 bilal@getfloe.com Company Website https://getfloe.com/

October 13, 2021 08:00 AM Eastern Daylight Time

Image

It’s Flu and Cold Season: How Over-the-Counter Remedies Can Help Relieve Cough and Chest Congestion

YourUpdateTV

As influenza activity begins to increase in October, now is the time to know how to navigate this cold and flu season. Recently, New York Times bestselling author, Dr. Ian Smith teamed with Mucinex and YourUpdateTV on a satellite media tour to discuss how to relieve cold, cough, and chest congestion symptoms. A video accompanying this announcement is available at: https://youtu.be/vfd-KUPmT3U While seasonal influenza viruses are detected year-round, flu viruses are most common during the fall and winter – kicking off in October. So, as we enter another unprecedented cold & flu season, we can still expect to see an increase in cold and flu cases between now and February. That said, according to Dr. Ian Smith, we should still continue to take key preventative measures to avoid catching any of these viruses. This includes wearing a mask in crowded public places, washing your hands often and covering your nose and mouth with a tissue or your elbow when you cough and sneeze to prevent the spread of germs. While there is no cure for the common cold or flu, there are over-the-counter medications that can help when you start to feel those classic cold and flu symptoms coming on. For instance, Mucinex has a line of 12-hour products that provide relief. Mucinex DM not only thins and loosens mucus, but also controls cough, providing relief for both wet and dry coughs, lasting up to 12 hours. And Mucinex 12 HR Extended Release Tablets help thin and loosen mucus to relieve chest congestion, and also provide relief for 12 hours. People must use over-the-counter products as directed. If your cold and flu symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. Dr. Smith also shared self-care recommendations such as exercising regularly and eating healthy. Activities like walking, strength training and yoga are good for the mind and the body. A diet full of nutritious meals packed with fruits and veggies and lean proteins like chicken or fish is also very important for a strong immune system. For more information on how to take care of yourself this cold and flu season, visit Mucinex.com for more information. About Dr. Dr Ian Smith: Dr. Ian Smith is the author of the #1 New York Times bestselling books, SHRED: THE REVOLUTIONARY DIET, and SUPER SHRED: The Big Results Diet, and BLAST THE SUGAR OUT. Dr. Smith’s highly anticipated newest book, The Clean 20, became an instant New York Times best seller, helping hundreds of thousands of people reduce bad sugars from their diet, lose weight, lower blood sugar levels, and cut the cravings. Dr. Smith was appointed by President Obama to a second term on the prestigious President’s Council on Fitness, Sports, and Nutrition. He is currently the medical contributor and co-host of the nationally syndicated television show The Rachael Ray Show. He is a former co-host of the Emmy award winning syndicated daytime talk show, The Doctors. He also served as the medical/diet expert for six seasons on VH1’s highly-rated Celebrity Fit Club, and is the creator and founder of the national health initiatives The 50 Million Pound Challenge and The Makeover Mile. Dr. Smith is the former medical correspondent for NBC News network and for NewsChannel 4 in New York, where he filed reports for NBC Nightly News and The Today Show as well as WNBC’s various news broadcasts. He has appeared extensively on various broadcasts including The Oprah Winfrey Show, The View, Dr. Oz, Steve Harvey Show, The Talk, Larry King Live, Anderson Cooper 360, CNN, MSNBC and many more. He has written for various publications including Time, Newsweek, Men’s Fitness, and the New York Daily News, and has been featured in several other publications including, People, Redbook, Details Magazine, Essence, Ebony, University of Chicago Medicine on the Midway, Cosmopolitan, and Black Enterprise. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 12, 2021 11:09 AM Eastern Daylight Time

Video

Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing cell therapy treatments for ALS and diabetes, announced today that the Company held a preliminary meeting with the FDA (INTERACT) on October 7, 2021 regarding IsletRx, the company’s cell therapy product in development for the treatment of diabetes. During the meeting, Kadimastem received a response document from the FDA noting that the company’s clinical development plan for IsletRx was being positively considered. It also included constructive comments and guidelines applicable for the next step pre-IND submission. This interaction is of great importance to Kadimastem’s clinical product development process and is an important milestone for the company. It was Kadimastem’s first meeting with the FDA regarding its diabetes project and the FDA’s first review of IsletRx, which demonstrated positive results in preclinical trials. IsletRx is an expanded population of allogeneic stem cells differentiated into functioning insulin producing pancreatic islet cells. The company then uses a proprietary technology to select the purest performing cells from its population and puts them into a microcapsule that protects the cells from being rejected by the body’s immune system. The implanted cells have shown in preclinical studies to be able to detect the sugar levels in the body and to, produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas. Kadimastem CEO Asaf Shiloni said, "Thanks to Dr. Kfir Molakandov, the Director of Diabetes at Kadimastem, who presented the IsletRx project in an impressive manner, we received a positive response to the company’s clinical development outline from the FDA's expert team, who we believe were overall very impressed with our technology. The FDA’s expert team provided us with important feedback that we will use to prepare for the next step, our Pre-IND submission for IsletRx. I am convinced that the successful meeting and the relevant feedback will contribute to the continued progress of our product development and if all goes well, ultimately provide a cure for those living with diabetes.” Kadimastem Chief Scientist Professor Michel Revel said, “The INTERACT meeting with the FDA is an important step forward and shows that Kadimastem's development plan for its diabetes treatment product, IsletRx, is in the right direction.” About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to cure patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021 where the diabetes treatment program was discussed and the company received directions how to prepare its Pre-IND submission. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Must Have Communications Marjie Hadad marjie@mhc-pr.com Kadimastem Sarah Herzl +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

October 12, 2021 09:54 AM Eastern Daylight Time

US Digestive Health Announces Pilot with AI-Enhanced Endoscopy Aid Device, GI Genius

US Digestive Health

US Digestive Health, a management services organization created to expand access to high-quality, value-based gastroenterology care, began a trial with GI Genius, a state-of-the-art AI-enhanced endoscopy aid device for the detection of colorectal lesions during colonoscopy. GI Genius utilizes artificial intelligence to improve detection of colorectal cancer during screening colonoscopy procedures. Medtronic received approval from the FDA in April of this year. US Digestive Health initiated a trial of the new technology in July 2021 and is the first practice in Pennsylvania to offer GI Genius. “We are constantly researching and investing in ways to help our providers detect potentially cancerous lesions,” said Dr. Dale Whitebloom, Chief Medical Officer of US Digestive Health. “We want the very best for our patients and if AI helps us to detect cancerous and precancerous lesions more effectively then we want to explore it thoroughly.” GI Genius is a combination of hardware and software that helps identify regions of interest during the colonoscopy. The device is not intended to replace lab sampling or suggest a course of action to the physician – but it does aid in highlighting areas of concern for providers to address. “US Digestive Health is committed to bringing the latest advances in colorectal cancer screening to our communities,” said Jerry Tillinger, CEO of US Digestive Health. “We are proud to be the first practice in Pennsylvania to deploy this incredible technology for our patients.” With offices throughout Central and Southeastern Pennsylvania, including the Greater Philadelphia region, US Digestive Health works hand-in-hand with gastroenterology partner practices to meet the challenges of a fast-changing healthcare landscape. By providing innovative business management and technology solutions that ease administrative burdens and support their financial success, US Digestive Health allows physicians to stay focused on delivering great patient care. US Digestive Health was formed in 2019 by Amulet Capital Partners, LP (“Amulet”), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians. For more information, visit https://usdigestivehealth.com/ About US Digestive Health As the leading gastroenterology practice on the East Coast, US Digestive Health is at the forefront of the rapidly advancing science of digestive health, bringing new insight into the care, treatment and prevention of digestive health disorders. For more information, visit https://usdigestivehealth.com. About Amulet Capital Partners, LP Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit www.amuletcapital.com. Media Contact for Amulet Capital Partners, LP Melissa Sheer Kent Place Communications, LLC 917-690-2199 melissa@kentplacellc.com Contact Details Noah Ramagano nramagano@usdhealth.com Company Website https://usdigestivehealth.com

October 12, 2021 07:56 AM Eastern Daylight Time

MOTIS Brands Acquires Mac’s Custom Tie-Downs

Rotunda Capital Partners LLC

MOTIS Brands (“MOTIS”), a Rotunda Capital Partners portfolio company, has acquired Mac’s Custom Tie-Downs (“Mac’s”), a leading manufacturer of high-quality tie-down systems for trailers and truck beds. For nearly 30 years, Mac’s has been innovating and producing tie-down solutions from their headquarters in Sagle, Idaho. The acquisition of Mac’s adds another premium brand to MOTIS’s portfolio of loading, hauling, automotive, and accessibility brands, and further strengthens its position as a leader in truck and trailer cargo control. “We are excited to add Mac’s line of outstanding products and their talented team to the MOTIS family of brands,” said MOTIS CEO Rich Spratt. “Mac’s adds additional U.S. manufacturing capabilities and another strong brand to our assortment. Our goal remains to assemble the broadest and deepest collection of premium products for loading, hauling, storage and productivity needs, and Mac’s is an ideal addition to our offering.” About MOTIS Brands Headquartered in Germantown, WI, MOTIS Brands proudly designs, develops, and distributes a collection of industry leading loading, hauling, automotive and accessibility brands including Race Ramps®, Silver Spring Mobility®, Heavy Duty Ramps™, Black Widow®, Guardian Industrial Products™, Kill Shot®, Tilt-a-Rack®, Harbor-Mate®, Lucky Dog™, Big Boy®, and Mac’s Custom Tie-Downs. For more information, visit www.motisbrands.com. About Rotunda Capital Partners Rotunda Capital Partners is a private equity firm that invests equity capital in established, lower middle market companies. Rotunda partners with management to build data-driven growth platforms within its targeted sectors, including value-added distribution, asset light logistics and industrial/business services. Founded in 2009, the firm has a long history of helping management teams achieve their goals for growth. The Rotunda team actively provides guidance and draws on deep industry and financial relationships to contribute to the successful execution of Rotunda’s companies’ strategic plans. The firm has offices in Bethesda, MD and Evanston, IL. For more information, visit www.rotundacapital.com. Contact Details Jill Lafferty +1 847-280-1295 jill@rotundacapital.com Company Website https://www.rotundacapital.com

October 12, 2021 07:34 AM Eastern Daylight Time

Harrods enters the limited-edition sneaker market welcoming The Edit LDN

Stockwood Strategy

The UK’s leading online store for limited edition sneakers and high-end streetwear The Edit LDN, today announced the opening of its first ever UK boutique store in Harrods, one of London’s most famous department stores. Harrods visitors will be able to see, experience and buy the latest limited-edition sneakers from The Edit LDN. Already popular with royalty, celebrities and footballers, The Edit LDN is a leading online destination that sells the hottest and hardest to get sneakers and streetwear from brands including Yeezy, Jordan, Off-White and collaborations through to Supreme, among others to a wide community of fashionistas, collectors and investors. Just as premium sites like Farfetch address the fashion world, The Edit LDN showcases the latest sneakers and high-end streetwear. They connect premium resellers with a highly engaged, price agnostic and eager audience. Moses Rashid, Founder and CEO of The Edit LDN commented: “We want to expand and increase accessibility for people who want to own limited edition sneakers around the world. Being the first sneaker reseller in Harrods is a proud and milestone moment for the company and its great to see such a global mega brand engaging with the sneaker market, moreover, that we're the catalyst to make that happen. Harrods offers an amazing customer journey to their global customer base and this aligns completely with our approach, to offer the best in class service. In 18 months, we have expanded our community of buyers from avid sneaker fans to TV and film celebrities as well as professional footballers and royal families around the world. Opening in Harrods is a logical next step as we bring our unique proposition to their customer base”. The Edit LDN has established itself as a trusted source of authenticated and high quality new and pre-loved streetwear and sneakers. Their unabating focus on speed (to deliver purchased goods), customer service engagement and ensuring all goods are authenticated has been testament to the growth of the platform and community. Simon Longland, Head of Menswear at Harrods commented: “Over the past three years, menswear at Harrods has undertaken a huge transformation, that has been visible through our brand curation as well as the physical shop floor. Our goal has been to transform the menswear experience at Harrods and embrace the most important and desirable trends on the market, and the launch of The Edit LDN continues that strategy. Bringing The Edit LDN’s industry expertise to Harrods ensures that our customers have access to the latest and most exclusive styles on the market through a service level which is unmistakably Harrods.” Helen David, Chief Merchant at Kurt Geiger added: “We’ve been at the forefront of embracing the latest trends serving a wide and diverse range of customers. What used to be considered sportswear is now considered luxury, and the shoes that are the most wanted and the hottest tickets are now sneakers. Without this as part of our matrix at Harrods, we wouldn’t have a proper 360 luxury offer. Hosting The Edit LDN at Harrods is testament to our commitment of meeting our customer needs with the market-leader in the premium sneaker business. Our shared objective with The Edit LDN is to ensure that Harrods’ customers have access to the latest and best on the market to meet their lifestyle needs.” Looking ahead, Moses said: “This is a marketplace worth $6b a year globally and will grow 5x by 2030. The demand for sneakers is growing every day and we are at the heart of servicing this trend. It’s been a remarkable 18 months since we launched to now opening in Harrods, the world’s most iconic department store. We are in hyper growth and headed in the right trajectory as we scale the business globally. Our on-going funding round will enable us to move faster and achieve our goals“. About The Edit LDN Founded in 2020, The Edit LDN has quickly become the UK’s leading online consignment store for limited edition sneakers and high end streetwear, both new and pre-loved items. Their innovative platform connects premium resellers to a global audience offering a deluxe experience from discovery, packaging and delivery. Brands include Jordan, Yeezy, Louis Vuitton, Dior, Off-White, Supreme, Fear of God among others. The platform is fast becoming synonymous with speed of service, authenticity, diverse selection of secure payment methods, and first class customer service. The Edit LDN is the leading destination for resellers and their premium sneakers and streetwear. Through partnerships with styling services such as Thread.com and various concierge companies, The Edit LDN has a community of buyers celebrities to professional footballers and royal families around the world. Further information visit: www.theeditldn.com. You are welcome to follow us on LinkedIn, Facebook or Instagram About Harrods Harrods began as a wholesale grocer and tea merchant in east London, first opening its doors in 1834. Since then, it has grown to become the world’s most famous department store, known for its unrivalled range of luxury merchandise. As well as exclusive brands and myriad departments, one of Harrods’ most renowned attributes is its unparalleled service. Harrods continues to be guided by its philosophy of “anything is possible” and, to this day, our customers remain at the heart of everything we do. Harrods.com About Kurt Geiger Kurt Geiger is a premium footwear brand operating across the UK. It first opened its doors on Bond Street in 1963. Kurt Geiger's own brands for women, men and children include Kurt Geiger London, KG, Carvela and Miss KG. Kurt Geiger has operated the Harrods and Selfridges footwear departments for the past 25 years. This unique positioning sets Kurt Geiger apart as a distinctive and unparalleled multi-channel business selling third-party and owned brands through department store concessions. The brand has over 80 stores worldwide, kurtgeiger.com, as well as e-commerce concession sites and wholesale partners. Selling over four million pairs of shoes a year this makes Kurt Geiger the largest luxury footwear retailer in Europe. Contact Details The Edit LDN Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.theeditldn.com/

October 11, 2021 09:00 AM Eastern Daylight Time

Image

Motor vehicle crash victims more likely to suffer harm in the hospital reports Patient Safety Authority

Patient Safety Authority

Patients who have experienced trauma from a motor vehicle crash are more likely to suffer harm when they go to the hospital in Pennsylvania compared to other patients. That’s according to the Patient Safety Authority (PSA) and the first-of-its-kind analysis of safety events in the hospital involving patients admitted following a motor vehicle crash. The report was published in the September 2021 issue of PATIENT SAFETY. Every hour in Pennsylvania, there are about 14 motor vehicle crashes—with one fatality every 8 hours—according to the Pennsylvania Department of Transportation (2019). More than 200 people are injured in crashes every day, many of whom wind up in the hospital. The information, from PSA’s patient safety database, PA-PSRS, is from 2018–2020. “Typically, 3% of reports of patient safety events are classified as serious,” says researcher Elizabeth Kukielka, PharmD, MA, RPh. “However in this study, we found that number more than quadrupled, with more than 13% of reports being classified as serious events. “We must be cautious in drawing conclusions about why, as this could have as much to do with the patient’s condition upon arrival at a hospital as it does with the actions of healthcare providers.” Crash victims who wind up in the emergency room are often unconscious, physically incapacitated or suffering from confusion, impacting their ability to participate in their own care. “That could lead to communication breakdowns,” says Kukielka. In addition to issues with communication, contributing factors to patient harm include lack of policies or awareness of existing policies, and prioritizing the patient’s condition from the crash over underlying health conditions. Other topics in this issue of PATIENT SAFETY include: Elder suicide in skilled nursing facilities – In Pennsylvania, people 65 and older are five times more likely to commit suicide than people under 20. Moving to a nursing home can be an especially difficult, high-risk period, so facilities should do a mental health screening, especially learning about the resident’s pre-admission behavior patterns. Safety trade-offs in home care during COVID-19 - A new study examined home care workers’ experience during COVID-19. Not surprisingly, they often prioritized patient needs over their own, despite the high-risk, low-pay nature of the job. The study reaffirms the need for a focus on improved safety protocols for vulnerable home care patients and workers. The impact of COVID-19 on medical device reporting and investigation – While the impact of COVID-19 on patient care is still unfolding, what about its impact on investigating malfunctioning medical devices? A study found that delays were due to travel bans, limited capabilities (e.g. stay-at-home-orders), device contamination concerns, patients’ reluctance to visit their doctor and cancellations of elective procedures. The potential consequences: a backlog of uninvestigated devices, lost information over time and lack of post market surveillance leading to adverse events that could have otherwise been prevented. PATIENT SAFETY is the peer-reviewed journal of the Patient Safety Authority. A scientific publication, PATIENT SAFETY humanizes patient harm with stories, opinion pieces, and magazine-quality design. It has a readership of more than 45,000 people in 164 countries. About PSA Established under the Medical Care Availability and Reduction of Error (MCARE) Act of 2002, the PSA, an independent state agency, collects and analyzes patient safety data to improve safety outcomes and help prevent patient harm. http://patientsafety.pa.gov/ Contact Details Bev Volpe +1 609-230-4696 bev@madisongall.com Company Website http://patientsafety.pa.gov/

October 08, 2021 10:27 AM Eastern Daylight Time

Image

ThreatModeler Announces Commitment to Global Cybersecurity Advocacy Efforts as a 2021 Cybersecurity Awareness Month Champion

National Cyber Security Alliance

Automated Threat Modeling Leader Becomes Joins Worldwide Initiative to Reinforce the Importance of Proper Cybersecurity Protection Measures for Individuals and Organizations in an Increasingly Connected World ThreatModeler today announced its commitment to Cybersecurity Awareness Month, held annually in October, by signing up as a 2021 Champion and joining a growing global effort to promote the awareness of online safety and privacy. The Cybersecurity Awareness Month Champions Program is a collaborative effort among businesses, government agencies, colleges and universities, associations, nonprofit organizations and individuals committed to the Cybersecurity Awareness Month theme of ‘Do Your Part. #BeCyberSmart.’ “At ThreatModeler, we empower organizations to securely develop their most crucial applications and infrastructure.” said Archie Agarwal, Founder and CEO of ThreatModeler. “In line with Cybersecurity Awareness Month, ThreatModeler is proud to continue our work in championing industry best practices and ensuring organizations have the knowledge and the tools to stay well ahead of major vulnerabilities moving forward.” More than ever before, technology plays a part in almost everything we do. Connected devices have been woven into society as an integral part of how people communicate and access services essential to their wellbeing. Despite these great advances in technology and the conveniences this provides, recent events have shown us how quickly our lives and businesses can be disrupted when cyber criminals and adversaries use technology to do harm. Cybersecurity Awareness Month aims to shed light on these security vulnerabilities, while offering actionable guidance surrounding behaviors anyone can take to protect themselves and their organizations. Everyone has a responsibility to do their part in securing our interconnected world. This year, the Cybersecurity Awareness Month’s main weekly focus areas will revolve around: Understanding and implementing basic cyber hygiene, including the importance of strong passphrases, using multi-factor authentication, performing software updates and backing up data. Recognizing and reporting phishing attempts whether it’s through email, text messages, or chat boxes. Empowering individuals to not only practice safe online behavior, but consider joining the mission of securing our online world by considering a career in cybersecurity! Making cybersecurity a priority in business by making products and processes “secure by design” and considering cybersecurity when purchasing new internet-connected devices. If everyone does their part – implementing stronger security practices, raising community awareness, educating vulnerable audiences or training employees – our interconnected world will be safer and more resilient for everyone. Now in its 18th year, Cybersecurity Awareness Month continues to build momentum and impact with the ultimate goal of providing everyone with the information they need to stay safer and more secure online. ThreatModeler is proud to support this far-reaching online safety awareness and education initiative which is co-led by the National Cyber Security Alliance and the Cybersecurity and Infrastructure Agency (CISA) of the U.S. Department of Homeland Security. For more information about Cybersecurity Awareness Month 2021 and how to participate in a wide variety of activities, visit staysafeonline.org/cybersecurity-awareness-month/. You can also follow and use the official hashtag #BeCyberSmart on social media throughout the month. About ThreatModeler ThreatModeler is an automated platform that provides a sustainable, self-service threat modeling practice for applications and infrastructure that evolves as your infrastructure grows. ThreatModeler encourages collaboration through its simple process flow diagram-based functionality that’s easy to use in the creation of threat models that identify, prioritize and mitigate threats, while communicating them broadly. ThreatModeler integrates with JIRA, Jenkins, and Azure Boards and Pipelines, with bidirectional web services API also unifying stakeholders in collaboration. Teams are empowered to code fearlessly and deliver new products with security built in as early as the design phase, which is based on global security and compliance standards. About Cybersecurity Awareness Month Cybersecurity Awareness Month is designed to engage and educate public- and private-sector partners through events and initiatives with the goal of raising awareness about cybersecurity to increase the resiliency of the nation in the event of a cyber incident. Since the Presidential proclamation establishing Cybersecurity Awareness Month in 2004, the initiative has been formally recognized by Congress, federal, state and local governments and leaders from industry and academia. This united effort is necessary to maintain a cyberspace that is safer and more resilient and remains a source of tremendous opportunity and growth for years to come. For more information, visit staysafeonline.org/cybersecurity-awareness-month/ About National Cyber Security Alliance The National Cyber Security Alliance is a nonprofit alliance on a mission to create a more secure connected world. We enable powerful, public-private partnerships in our mission to educate and inspire individuals to protect themselves, their families and their organizations for the collective good. Our primary partners are the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency (CISA) and our Board of Directors, which includes representatives from ADP; AIG; Bank of America; Cofense; Discover; Eli Lilly and Company; ESET North America; Facebook; KnowBe4; La-Z-Boy; Lenovo; Marriott International; Mastercard; Microsoft; Mimecast; NortonLifeLock; Paubox; Proofpoint; Raytheon Intelligence & Space; Terranova Security; US Bank; VISA; Wells Fargo. The National Cyber Security Alliance’s core efforts include Cybersecurity Awareness Month (October); Data Privacy Day (Jan. 28); Identity Management Day; and CyberSecure My Business™. For more information on the National Cyber Security Alliance, please visit https://staysafeonline.org. Contact Details Mike Stolyar threatmodeler@luminapr.com Company Website https://www.threatmodeler.com

October 07, 2021 09:00 AM Eastern Daylight Time

1 ... 256 257 258 259 260 ... 309